Prolonged Serum Insulin Decreasing Effects of Two Synthetic Somatostatin Analogues Studied in vivo by a New Animal Method

References

• Alberti K. G. M. M., Christensen Juel N., Christensen Engkjær S., Hansen Aa. Prange, Iversen J., Lundbæk K., Sayer-Hansen K., Ørskov H. Inhibition of insulin secretion by somatostatin. Lancet 1973; II: 1299
   Google Scholar
• Bloom S. R., Mortimer C. H., Thorner M. O., Besser G. M., Hall R., Gomez-Pan A., Roy V. M., Russel R. C. G., Coy D. H., Kastin A. J., Schally A. V. Inhibition of gastrin and gastric-acid secretion by growth-hormone release inhibiting hormone. Lancet 1974; ii: 1106
   Google Scholar
• Efendić S., Luft R. Studies on the inhibitory effect of somatostatin on glucose induced insulin release in the isolated perfused rat pancreas. Acta Endocr (Kbh.), 1975; 78: 510
   PubMedGoogle Scholar
• Gerich J. E., Lorenzi M., Schneider V., Forsham P. H. Effect of somatostatin on plasma glucose and insulin response to glucagon and tolbutamide in man. J Clin Endocr Metab 1974; 39: 1057
   PubMed Web of Science ®Google Scholar
• Gerich J. E., Lovinger R., Grodsky G. M. Inhibition by somatostatin of glucagon and insulin release from the perfused rat pancreas in response to arginine, isoproterenol and theophylline. Evidence for a preferential effect of glucagon secretion. Endocrinology 1975; 96: 749
   PubMed Web of Science ®Google Scholar
• Guillemin R., Gerich J. E. Somatostatin: physiological and clinical significance. Ann Rev Med 1976; 27: 379
   PubMed Web of Science ®Google Scholar
• Hales C. N., Randle B. J. Immuno-assay of insulin with anti-body precipitate. Biochem J 1963; 88: 137
   PubMed Web of Science ®Google Scholar
• Hansen A. P., Lundbaek K. Somatostatin: A review of its effects, especially in human beings. Diabete Metabolisme (Paris) 1976; 2: 203
   PubMedGoogle Scholar
• Herbai G., Westman-Naeser S., Carlsson L., Mulder† Melin P. J. The dose dependent serum insulin lowering effect of somatostatin (GH-RIF) in vivo in the obese-hyperglycaemic (ob-ob) syndrome. Ups J Med Sci. 1977; 82: 255
   Google Scholar
• Hökfelt T., Efendić S., Hellerström C., Johansson O., Luft R., Arimura A. Cellular localization of somatostatin in endocrine-like cells and neurons of the rat with special references to the A1-cells of the pancreatic islets and to the hypothalamus. Acta Endocr (Kbh) Suppl. 200, 1975; 80: 5
   Google Scholar
• Iversen J. Inhibition of pancreatic glucagon release by somatostatin: in vitro. Scand J Clin Lab Invest 1974; 33: 125
   PubMed Web of Science ®Google Scholar
• Johnson D. G., Ensinck J. W., Koerker D., Palmer J., Goodner C. J. Inhibition of glucagon and insulin secretion by somatostatin in the rat pancreas perfused in situ. Endocrinology 1975; 96: 370
   PubMedGoogle Scholar
• Leblanc J. R., Anderson M. B., Siegel M. B., Yen S. S. C. Inhibitory action of somatostatin on pancreatic α and β cell function. J Clin Endocrinol Metab 1975; 40: 568
   PubMed Web of Science ®Google Scholar
• Mortimer C. H., Turnbridge W. M. G., Carr D., Yeomans L., Lind T., Coy D. H., Bloom S. R., Kastin A., Mallinson C. N., Besser G. M., Schally A. V., Hall R. Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet 1974; i: 697
   Google Scholar
• Parker D. C., Rossman L. G., Siler T. M., Rivier J., Yen S. S. C., Guillemin R. Inhibition of the sleep-related peak in physiologic human growth hormone release by somatostatin. J Clin Endocr Metab 1974; 38: 496
   PubMedGoogle Scholar
• Patel Y. C., Alford F. P., Burger H. G. The 25-hour plasma thyrotrophin profile. Clin Sci. 1972; 43: 71
   PubMed Web of Science ®Google Scholar
• Peracchi M., Reschini E., Cantalamessa L., Giustina G., Cavagnini F., Pinto M., Bulgheroni P. Effect of somatostatin on blood glucose, plasma growth hormone, insulin, and free fatty acids in normal subjects and acromegalic patients. Metabolism 1974; 23: 1009
   PubMedGoogle Scholar
• Rivier J., Brazeau P., Vale W., Guillemin R. Somatostatin analogs. Relative importance of the disulfide bridge and of the Ala-Gly side chain for biological activity. J Med Chemistry 1975; 18: 123
   PubMedGoogle Scholar
• Sakurai H., Dobbs R. E., Unger R. H. The effect of somatostatin on the response of GLI to the intraduodenal administration of glucose, protein, and fat. Diabetologia 1975; 11: 427
   PubMed Web of Science ®Google Scholar
• Sarantakis D., McKinley W. A., Jaunakais I., Clark D., Grant N. H. Structure activity studies on somatostatin. Clin Endocrin 1976; 5(Suppl.)275s
   Google Scholar
• Siler T. M., Berg Vanden G., Yen S. S. C., Brazeau P., Vale W., Guillemin R. Inhibition of growth hormone release in humans by somatostatin. J Clin Endocr Metab 1973; 37: 632
   PubMed Web of Science ®Google Scholar
• Siler T. M., Yen S. S. C., Vale W., Guillemin R. Inhibition by somatostatin on the release of TSH induced in man by thyrotropin-releasing factor. J Clin Endocrinol Metab 1974; 38: 742
   PubMed Web of Science ®Google Scholar
• Vale W., Brazeau P., Rivier C., Brown M., Boss B., Rivier J., Burgus R., Ling N., Guillemin R. Somatostatin. Recent Progr Hormone Res 1975; 31: 365
   PubMedGoogle Scholar
• Vávra I., Machová A., Holeček V., Cort J. H., Zaoral M., Šorm F. Effect of a synthetic analogue of vasopressin in animals and in patients with diabetes insipidus. Lancet 1968; i: 948
   Google Scholar
• Weeke J., Hansen A. P., Lundbaek K. The inhibition by somatostatin of the thyrotropin response to thyrotropin-releasing hormone in normal subjects. Scand J Clin Lab Invest 1974; 33: 101
   PubMed Web of Science ®Google Scholar